Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Quotient Bioscience Group (United Kingdom) a provider of bioscience analytics and safety evaluation services, closed a $53M Series B financing. Participants include TA Associates.

Sagent Pharmaceuticals (Schaumberg, Illinois) commercial-stage specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products, closed a $83M Series A financing. Participants include Vivo Ventures.

Pathwork Diagnostics (Sunnyvale, CA) molecular diagnostics company focused on oncology, closed a $20M Series B financing. Participants include Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, Venrock and Versant Ventures.

VasoNova (Sunnyvale, CA) developer of a self-guided peripherally inserted central catheters, closed a $10M Series B financing. Participants include Arboretum Ventures, Aphelion Capital, Coronis Medical Ventures and Research Corporation Technologies, Coronis Medical Ventures and Life Science Angels.

ArKal Medical (Fremont, CA) developer of a continuous glucose monitoring system, closed a $17.5M Series B financing. Participants include Thomas McNerney & Partners, Delphi Ventures and MedVenture Associates.

Soteira (Natick, MA) developer of treatment for vertebral compression fractures, closed a $12M Series B financing. Participants include Delphi Ventures, Prism VentureWorks, Federated Kaufman Fund, HLM Venture Partners and Partech International.

Cocrystal Discovery (Seattle, WA) developer of antiviral therapeutics for the treatment of serious and chronic viral diseases, closed a $10M Series A financing. Participants include The Frost Group.

MonoSol Rx (Warren, NJ) drug delivery company specializing in the development and commercialization of thin film strip pharmaceutical drug products, closed a $10M Series C financing. Participants include Ed Bass Group, The Halifax Group, and CNF Investments.

Telormedix (Switzerland) developer of immunotherapeutics for cancer, closed a $19M Series A financing. Participants include Aravis Ventures, Proquest Investments, BSI SA, Nextech Venture and Generali Insurance Group.

Lumavita (Switzerland) early-stage specialty biopharmaceutical company focused on antiinfectives for women’s health, closed a $16M Series A financing. Participants include Atlas Ventures, BB Biotech Ventures, and BioMedInvest.

Histogenics (Waltham, MA) early-stage cartilage regeneration company developing products for joint repair, closed a $9M Series B financing. Participants include Boston Millennia Partners, Foundation Medical Partners, Altima Partners, Stryker Corporation and Inflection Point Partners.

Osprey Pharmaceuticals (San Francisco, CA) early-stage company focused on protein therapeutics for treating inflammatory disease, closed a $11M Series A financing. Participants include Burrill & Co., Novo Nordisk Biotech Fund, Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital and Western Technology Seed Investment Fund.

Spinifex Pharmaceuticals (Australia) pain drug development company, closed a $12M Series B financing. Participants include GBS Venture Partners Limited, Brandon Capital Partners and Uniseed.

« Previous Entries  Next Page »

to top of page...